Afatinib effective in erlotinib/gefitinib-resistant NSCLC

Afatinib is effective when given to patients with non-small-cell lung cancer who have progressed during treatment with erlotinib and/or gefitinib, phase II trial results reveal.
Source: MedWire News - Lung Cancer - Category: Cancer & Oncology Source Type: news